- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Interventions
- GEN-011, IL-2, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
- Interventions
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Streptococcus Pneumoniae
- Interventions
- Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 with Matrix M-2, GEN-003, Placebo
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
- Conditions
- Genital Herpes, HSV-2 Infection
- Interventions
- GEN-003, Matrix-M2, 0.9% normal saline
- Biological · Other
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg)
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- Matrix-M2, GEN-003, Placebo
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- Observational
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more